Completed OBSERVATIONAL NCT03183934

A Follow-up Study to Evaluate the Efficacy and Safety of ALLO-ASC-DFU in ALLO-ASC-EB-101 Clinical Trial

A Follow-up Study to Evaluate the Efficacy and Safety for the Patients With ALLO-ASC-DFU Treatment in Phase 1/2 Clinical Trial of ALLO-ASC-EB-101

Sponsor: Anterogen Co., Ltd.

Conditions Dystrophic Epidermolysis Bullosa

Interventions ALLO-ASC-DFU

Updated 9 times since 2017 Last updated: Aug 23, 2023 Started: Dec 8, 2017 Primary completion: Apr 20, 2018 Completion: Apr 30, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Dystrophic Epidermolysis Bullosa, this trial is completed. The trial is conducted by Anterogen Co., Ltd. and has accumulated 9 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Completed
Sep 2024 — Sep 2025 [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Sep 2023 — Jul 2024 [monthly]

Completed

Status: Unknown Status → Completed
Jan 2021 — Sep 2023 [monthly]

Unknown Status

▶ Show 4 earlier versions

Jul 2020 — Jan 2021 [monthly]

Unknown Status

Status: Not Yet Recruiting → Unknown Status
Jun 2018 — Jul 2020 [monthly]

Not Yet Recruiting
Apr 2018 — Jun 2018 [monthly]

Not Yet Recruiting

Phase: NA → None
Jul 2017 — Apr 2018 [monthly]

Not Yet Recruiting NA

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Anterogen Co., Ltd.

Data source: Anterogen Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea